Bortezomib Inhibits Nuclear Factor-κB–Dependent Survival and Has Potent <i>In vivo</i> Activity in Mesothelioma

Abstract

Inhibition of NF-kappaB constitutive activation in MMe cells by Bortezomib resulted in in vitro cytotoxicity along with apoptosis and in vivo tumor regression. Our results support the use of Bortezomib in the treatment of MMe and has led to a phase II clinical trial currently enrolling in Europe.